Some phthalate chemicals can affect hormone physiology in utero, resulting in adverse reproductive health outcomes in animal models. It is unknown whether these exposures are related to circulating maternal hormone concentrations during pregnancy. We used multivariate linear regression to estimate associations between phthalate metabolite concentrations and concurrent serum-free and total testosterone and estradiol (E 2 ) levels in 180 pregnant women in the Study for Future Families. We also examined associations between prenatal serum hormone concentrations and anogenital outcome in infants. All analyses were adjusted for appropriate confounding variables. Total testosterone, free testosterone, and E 2 concentrations ranged from 8 to 406 ng/dl, 0.03 to 1.2 ng/dl, and 529 to 40 600 pg/ml respectively. We observed an inverse association between log-sum di-2-ethylhexyl phthalate (DEHP) metabolite concentrations and lower log-total testosterone concentrations (K0.15, 95% CI K0.26, K0.04) and log-free testosterone (K0.15, 95% CI K0.27, K0.03). This relationship persisted regardless of fetal sex. Similarly, we observed an inverse association between log monobutyl phthalate (MBP) concentrations and log-total and -free testosterone concentrations in women carrying male fetuses. Monoethyl phthalate (MEP) concentrations were positively associated with log-total and -free testosterone concentrations in women carrying male fetuses (0.09, 95% CI 0.003, 0.17 and 0.10, 95% CI 0.01, 0.19 respectively). Prenatal hormone concentrations were not significantly associated with infant anogenital outcomes. Our preliminary data suggest that DEHP metabolite, MBP, and MEP exposures during pregnancy are associated with prenatal sex steroid hormone concentrations, but sex steroid hormone concentrations were not associated with infant reproductive outcomes.
Introduction
Phthalates are synthetic endocrine-disrupting chemicals that can affect sex steroid hormone concentrations, signaling, and function during gestation in rodent models (Fisher 2004) . Changes in hormone concentrations during this important reproductive programing and developmental window can lead to significant downstream birth defects in the offspring in animal models (Gray et al. 2006) . In humans, phthalate exposure during pregnancy is related to a number of adverse childhood health outcomes that may be hormone mediated, including reduced anogenital distance (AGD) and changes in sex-specific childhood behavior (Swan et al. 2005 , Engel et al. 2009 . Whether phthalate exposure during pregnancy is related to sex steroid hormone concentrations remains undetermined but may have important implications for fetal development and sex steroid-mediated health outcomes.
Exposure to di-2-ethylhexyl phthalate (DEHP), dibutyl phthalate (DBP), and benzylbutyl phthalate (BBzP) during gestation leads to reductions in testosterone concentrations in both the pregnant dam and in male offspring and subsequent adverse reproductive abnormalities in males , Kavlock et al. 2002 , Mylchreest et al. 2002 , Foster 2005 . In humans, prenatal exposure to DEHP has been negatively associated with free testosterone concentrations in the cord blood (Lin et al. 2011) . DEHP has also been negatively associated with estradiol (E 2 ) concentrations in adult female rodents and in vitro in ovarian granulosa cells via decreased aromatase transcription, but this relationship remains to be explored in pregnant women (Laskey & Berman 1993 , Davis et al. 1994 , Lovekamp-Swan & Davis 2003 . Studies examining the impact of diethyl phthalate (DEP) exposure during gestation have observed reduced testosterone concentrations but not reproductive tract defects in rodent offspring. (Fujii et al. 2005 , Howdeshell et al. 2008 .
The maternal, placental, and fetal compartments work in concert to produce circulating reproductive hormones during pregnancy, and the influence of each compartment changes depending on the gestational period (Tulchinsky et al. 1972 , Speroff & Marc 2005 , Strauss 2009 ). In early gestation, both the maternal and fetal compartments contribute to circulating hormone concentrations. In later gestation, the fetal adrenal glands provide the precursors for maternal estrogen and androgen production (Siiteri & MacDonald 1966 , Speroff & Marc 2005 . Therefore, circulating maternal hormone concentrations can reflect fetal production, and the influence of the fetal compartment increases as gestation progresses (Speroff & Marc 2005 , Strauss 2009 ). Total and free testosterone concentrations rise throughout pregnancy but not to the same extent as estrogens, and sources of the increased testosterone are not well characterized but are likely fetal in origin (Bammann et al. 1980 , Toriola et al. 2011 . The fetus controls estrogen production by producing androgens that are delivered to the placenta and aromatized, and the concentrations rise rapidly as pregnancy progresses (Siiteri & MacDonald 1966 , Madden et al. 1978 . Results on whether reproductive hormone concentrations differ by fetal sex in the first trimester of pregnancy are conflicting (Klinga et al. 1978 , Glass & Klein 1981 , but late in gestation, reproductive hormones in the fetal compartment and likely, to a great extent, those in the maternal compartment are reflective of fetal production and control (Speroff & Marc 2005 , Faupel-Badger et al. 2011 ). E 2 and testosterone are important sex steroid hormones that can impact maternal and fetal health (Melmed et al. 2011) . Estrogens are important for many homeostatic functions as well as for normal uteroplacental blood flow, mammary gland development, and fetal adrenal gland function during pregnancy (Speroff & Marc 2005 , Melmed et al. 2011 . Similarly, testosterone plays a role in several body functions and is important for reproductive function and appropriate development of the male genital tract during pregnancy (Speroff & Marc 2005 , Melmed et al. 2011 . The focus of this study is to examine the relationship between phthalate exposure and testosterone and E 2 concentrations in pregnancy as well as the relationship between prenatal hormones and infant reproductive outcomes.
Materials and methods

Study participants
Pregnant women were originally recruited in the first phase of the Study for Future Families (SFFI), a multicenter pregnancy cohort study, at prenatal clinics in Los Angeles, California, Minneapolis, Minnesota, Columbia, and Missouri, from September 1999 through August 2002. Methods are described in detail elsewhere (Swan et al. 2005) . Briefly, couples whose pregnancy was not medically assisted were eligible unless the woman or her partner was !18 years of age, either partner did not read and speak Spanish or English, or the father was unavailable or unknown. All participants completed a questionnaire and gave blood and urine samples on the same day, and the majority of samples were collected in the second or third trimester of pregnancy (98%). Eligibility criteria for the current analysis included data on prenatal urinary phthalate measurement, prenatal hormone measurement, and complete data on covariates. AGD is defined as the distance from the anus to anterior base of the penis in males and the distance from the anus to the anterior base of the clitoris in females. Anoscrotal distance (ASD) is the distance from the anus to the base of the scrotum, and ano-fourchette distance (AFD) is the distance from the anus to the base of the posterior fourchette. All measurements were performed in infants born to mothers in SFFI according to a standardized protocol described previously (Swan 2006) . In total, we analyzed data for 180 mothers who met these parameters. SFFI obtained human subjects approval, and all participants signed informed consents. The present analyses were deemed exempt for human subjects review, as all data were de-identified.
Serum hormone measurements
All hormone measurements were carried out at the Endocrine and Metabolic Research Laboratory at Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, using assays that have been fully validated and reported. Serum testosterone was measured by liquid chromatography tandem mass spectrometry (LC-MS/MS; Shiraishi et al. 2008) . Testosterone (O99% pure Sigma-Aldrich) was used as a calibration standard. 1,2 Deuterated (D 2 )-testosterone (O98% pure, Cambridge Isotope Laboratories, Inc., Andover, MA, USA) was used as the internal standard for T measurements. LC-MS/MS runs were carried out with a Shimadzu HPLC System (Columbia, MD, USA) attached to an Applied Biosystems API5000 LC-MS/MS equipped with a TurboIonSpray source. The calibration standards showed a linear response from 1 ng/dl (0.35 nmol/l) to 2000 ng/dl (69.3 nmol/l) for testosterone. The within-and between-run precision was !5% and the recovery of samples spiked with the steroids was between 100 and 113% for testosterone. The lower limit of quantification for testosterone was 2 ng/dl or 0.069 nmol/l (Shiraishi et al. 2008) . Free testosterone was measured by equilibrium dialysis using labeled testosterone as described previously (Qoubaitary et al. 2006) . Serum E 2 concentrations for all mothers of boys were measured with a validated LC-MS/MS method (Rothman et al. 2011) . Calibration standards and test samples were prepared for LC-MS/MS. First the proteins in the sera were precipitated using acetonitrile. The supernatant was dried and reconstituted with PBS and then extracted with 2 ml diethyl ether. LC-MS/MS was carried out with a Shimadzu HPLC system attached to an Applied Biosystems API5000 LC-MS/MS equipped with a TurboIonSpray source. The calibration standards showed a linear response from 1.0 to 1000 pg/ml for E 2 . Analysis of four pools with E 2 concentrations ranging from about 10 to 500 pg/ml showed the within-run precision range to be from 2.78 to 3.58%. The between-run precision for E 2 (computed over 27 runs) ranged from 3.7 to 9.8%. The recovery of samples spiked with the steroids was between 84.4 and 129% with a mean recovery of 101.8% for E 2 . The LOQ was 2 pg/ml for E 2 . Serum E 2 concentrations for mothers of girls were measured in 2003 in a different laboratory by RIA (Pantex, Santa Monica, CA, USA). The limit of detection (LOD) was 4.9 pg/ml and the inter-assay coefficient of variation was below 9%. We applied a correction factor to the concentrations of mothers of girls by RIA in order to use E 2 concentrations for all mothers in the analysis. The adjustment factor was created based on 156 samples of overlapping E 2 concentrations from 2003 and 2011. The values from 2003 were lower compared with those from 2011, but despite the differing concentrations, the data were highly correlated (0.99). We calculated the E 2 concentrations as (2011 E 2 
Phthalate metabolite measurements
The Division of Laboratory Sciences within the National Center for Environmental Health, Centers for Disease Control, conducted the analyses and had no access to participant data. The analytical method for urinary phthalate metabolites involved the enzymatic deconjugation of the metabolites from their glucuronidated form, followed by concentration of the analytes of interest by solid-phase extraction, separation with HPLC, and detection by isotope-dilution tandem mass spectrometry (Silva et al. 2004 , Kato et al. 2005 . This approach allows for the simultaneous quantification in human urine of the following phthalate metabolites reported in this work: monoethyl phthalate (MEP), monobutyl phthalate (MBP), monomethyl phthalate (MMP), MBzP, monoisobutyl phthalate (MiBP), mono-2-ethylhexyl phthalate (MEHP), and two oxidative metabolites of DEHP, mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP) and mono-2-ethyl-5-oxo-hexyl phthalate (MEOHP). Isotopically labeled internal standards and conjugated internal standards were used to increase precision and accuracy of the measurements. Quality control and reagent blank samples were analyzed along with unknown samples to monitor performance of the method. Urinary creatinine was measured at the time of phthalate analysis.
Statistical analysis
We examined the range of all exposure and outcome variables under consideration including concentration and distribution of maternal serum hormone concentrations and urinary phthalate concentrations. Because the distributions for total testosterone, free testosterone, and E 2 were right skewed, we used log transformations in all statistical analyses. Most phthalate metabolite concentrations were above the LOD, which was between 0.95 and 1.07 mg/l, depending upon the analyte. Concentrations below the LOD were assigned a value equal to the LOD divided by the square root of two (Hornung & Reed 1990 ). The percent of samples below the LOD for each of the phthalate metabolites was !15% except for MMP, which was over 50%. We chose not to include MMP in the statistical analyses. All phthalate metabolite concentrations were logarithmically transformed to normalize distributions. MEHP, MEOHP, and MEHHP are metabolites of a single parent compound (DEHP). Therefore, we used the molar sum of these metabolites to reflect total DEHP exposure.
We examined the bivariate relationship between the covariates chosen a priori and log hormone concentrations. We chose these factors based on past studies examining prenatal hormone concentrations as well as studies examining phthalate exposures. Based on this analysis, we included maternal age, gestational age at blood draw, and urinary creatinine as continuous covariates. We included study center, parity, and education as categorical covariates. We used linear regression to explore the associations between log-transformed prenatal phthalate metabolite concentrations and concurrent log-transformed maternal total testosterone, free testosterone, and E 2 concentrations in individual models.
We fit two models with and without sex-by-phthalate interactions. We reported both sets of results regardless of the significance of the interaction, as others have done (Sagiv et al. 2012 ). The first model assumes a common slope for boys and girls. The second model allows for separate slopes for boys and girls with the inclusion of sex by phthalate interaction terms (see equation 1). We used this model in order to avoid a loss of power from traditional stratification methods.
Sex-specific linear regression model*
C ðSEXÞb 3 C COVARIATES *where sex is coded as 0Zboys, 1Zgirls. We used multivariate linear regression to explore the associations between log-transformed prenatal hormone concentrations and AGD, ASD, and AFD in male and female infants separately. All analyses were adjusted for weight percentile of infant, age of infant, study center, gestational age at blood draw, and maternal age.
Results
The 180 pregnant women included in the analyses were primarily white (79%) and aged between 20 and 40 years (97%). Women were highly educated (O68% with at least a college degree), and 98% were in their second or third trimester of pregnancy at the time of blood and urine collection (Table 1) . Within this group, the highest urinary phthalate concentrations were observed for MEP, and the lowest for MIBP (Table 2) . Total testosterone concentrations ranged from 8 to 406 ng/dl, and free testosterone concentrations ranged from 0.03 to 1.2 ng/dl. E 2 concentrations ranged from 560 to 40 600 pg/ml (log values are shown in Figs 1a, b and 2a, b). In bivariate analysis of participant characteristics and hormone concentrations, increased maternal age and parity were associated with reduced log testosterone and log-free testosterone. Ethnicity was not significantly associated with any hormone concentrations. Having graduated college or technical school was significantly associated with lower testosterone concentrations in pregnant women, but this relationship was not significant in the higher educated women. Increasing gestational age was significantly associated with E 2 concentrations but not testosterone concentrations.
In the third trimester of pregnancy, female sex was associated with reduced log-total and log-free testosterone concentrations and increased log E 2 concentrations (Table 3 ).
Within the model that estimated sex-specific slopes, we observed a lower log-total concentration in relation to a log unit increase in the sum of DEHP metabolites in women with both male (K0.07, 95% CI K0.20, 0.06) and female fetuses (K0.15, K0.26, K0.04), but this result was only statistically significant for women carrying female fetuses (Table 4) . We observed similar results with log-free testosterone in relation to the sum of DEHP metabolites. We observed some evidence for effect modification for MBP and MBZP in relation to log-total and -free testosterone concentrations, with positive estimates for women with male fetuses and negative estimates for women with female fetuses. We also observed a higher log-total testosterone concentration in relation to a log unit increase in MEP (0.09, 95% CI 0.003, 0.17) in women with male fetuses only ( Table 4) . None of the prenatal log hormone concentrations were associated with AGD, ASD, or AFD in male or female infants (Table 5) .
Discussion
We report an association between increased prenatal DEHP metabolite exposure and lower testosterone concentrations in women carrying both male and female fetuses, and MBP was also associated with lower testosterone concentrations but only in women carrying female fetuses. We found the opposite relationship with increasing MEP exposure associated with higher testosterone concentrations, and this relationship was strongest in women with male fetuses. We did not find an association between prenatal hormone concentrations and infant anogenital outcomes. These findings are preliminary and based on a small sample size but suggest that exposure to some phthalates during pregnancy may affect sex steroid hormone concentrations.
Free testosterone is unbound and is bioavailable to peripheral tissues while total testosterone reflects both bound and free testosterone concentrations (Speroff & Marc 2005) . The Pearson's correlation coefficient between the total and free testosterone was O0.9, and regression results were similar for both, which supports the validity of both the hormonal and statistical analyses. The origin of prenatal circulating testosterone concentrations in humans is unclear but is thought to be primarily directed by the fetus as pregnancy progresses via fetal testicular Leydig cell production (Bammann et al. 1980 , Kerlan et al. 1994 . In women carrying female fetuses, testosterone is likely produced in a similar manner to nonpregnant women, through ovarian, adrenal gland, and peripheral production (Speroff & Marc 2005) . From our results, it may be that DEHP metabolites are both exerting an effect on adrenal as well as Leydig cell production of testosterone because we see reductions in testosterone concentration in women carrying both male and female fetuses. Testosterone plays an important role in sex differentiation during early human gestation. In male fetuses, increasing testosterone concentrations lead to virilization and normal development of male genital structures. In females, estrogen is the predominant sex steroid hormone and increased testosterone concentrations can lead to abnormal virilization (Speroff & Marc 2005) . In addition, normal estrogen and testosterone play an integral role in an adult female's general endocrine homeostasis and are known to be associated with a variety of health outcomes (Longcope 1986 ).
In animal studies, DEHP and DBP exposure in pregnant dams leads to lower intra-testicular testosterone concentrations in male offspring via a direct testicular toxic effect on Leydig cells , Foster 2005 , Howdeshell et al. 2008 . Therefore, our study may suggest that DEHP could be acting via a direct testicular toxic effect on fetal Leydig cells leading to reductions in circulating maternal testosterone concentrations. It is unclear whether DEHP exposure could also affect ovarian, adrenal, or androstenedione production of testosterone as there are no studies of this mechanism in the literature. Several studies suggest that DEP, an endocrine-disrupting chemical, is not as potent as DEHP or DBP, but one study did observe reduced testosterone concentrations in male offspring of pregnant dams exposed to DEP at 3000 and 15 000 ppm during gestation , Fujii et al. 2005 , Howdeshell et al. 2008 , and some human epidemiologic studies have found relationships between DEP exposure and adverse endocrine and reproductive health outcomes (Lopez-Carrillo et al. 2010 , Tranfo et al. 2011 . Results of our study suggest that DEP may be acting via a novel mechanism in relation to increased prenatal circulating testosterone concentrations given that we observed an increase in testosterone concentrations in women carrying male fetuses. Another possibility is that the DEP finding is due to chance alone. During gestation, E 2 production occurs primarily in the placenta through aromatization of androgens (Speroff & Marc 2005) . BBzP and DBP have been associated with weak estrogenic activity, but other studies have documented an anti-estrogenic effect in the peripheral tissues (Jobling et al. 1995 , Lee et al. 2004 . In two studies of rodent models, circulating estrogen concentrations of adult females were decreased in relation to high-dose DEHP exposure (Davis et al. 1994 , Hirosawa et al. 2006 . Overall, the impact of phthalate exposure on estrogen steroidogenesis is not well understood, with conflicting results in the literature. 
S Sathyanarayana and others
We observed the suggestion of lower E 2 concentrations in relation to increased DEHP exposure (as well as in the sex-specific analyses), but this association was not statistically significant. We examined the relationship between prenatal sex steroid hormones and sex-specific AGD within the SFFI dataset but did not observe any statistically significant relationships. However, this analysis was limited in several ways including exposure misclassification as well as a lack of precision in outcomes. The timing of serum collection was not appropriate. The genital reproductive programing window is early in pregnancy and the majority of the SFFI (O90%) serum samples were taken late in the second trimester or within the third trimester of pregnancy when they are less likely to have impacted genital development. The age of the infants at AGD exam was highly variable (9-36 months), making it more difficult to detect associations if they existed. Future studies would need to assess hormone concentrations in the first trimester of pregnancy when genital structures develop and then examine genital outcomes at birth.
Limitations of our study included spot urine samples to reflect urinary phthalate exposures. Although there can be variability in phthalate concentrations over time, several studies suggest that a spot sample can be representative of a 3-month period of exposure in adult women (Hoppin et al. 2002) . One study of phthalate variability in pregnancy showed that DEHP metabolites decreased as the pregnancy progressed while MEP and MiBP concentrations increased (Braun et al. 2012) . If these findings are generalizable, urine DEHP metabolite concentrations in our study may have been an underestimate of exposure during the first trimester while MEP concentrations could have been an overestimate. Urine and serum were collected at the same time for each woman. Ideally, we would like to have serum collected after the urine samples as it is not clear whether an effect would be seen concurrently or after hours or days. We did not have multiple measurements within the same women, which would allow for longitudinal analysis to examine changes in concentrations. We had samples from different time points during pregnancy and attempted to correct this by adjusting for gestational age at blood draw in our statistical analyses. Regardless, residual confounding by covariates in the analysis could introduce bias in the analysis. We conducted two sensitivity analyses. The first excluded the first trimester samples (nZ4), and results were unchanged. We then restricted analyses to women in the third trimester only (nZ96) and found that all estimates were in the same direction and of similar magnitude to the primary analysis. We were unable to directly assess fetal hormone concentrations in this study, and methodology to do this (amniotic fluid collection) would not be feasible in the general population.
Conclusion
Exposure to DEHP, MBP, and MEP during pregnancy may be related to changes in circulating prenatal testosterone concentrations. If confirmed, these findings are significant because testosterone is involved in the development of maternal and infant health outcomes including cardiovascular disease, hormone-mediated reproductive disease, neurodevelopmental outcomes, and fetal genital tract development. These results are preliminary and should be confirmed in future larger human cohort studies.
Discussion from meeting
Maria Andersson (Copenhagen, Denmark): You discovered two gene variants, one associated with decreased anogenital distance (AGD) and one with anoscrotal distance (ASD). There is no change in the coding regions of the genes, but is there any functional difference due to altered expression? Sheela Sathyanarayana (Seattle, USA): There is increased expression of the ATF3 gene in rats and this is validated in studies of human foreskin cells.
Anna-Maria Andersson: There is increased testosterone in the serum of young mothers under the age of 20 years. Is this associated with smoking or social class? Smoking is known to increase testosterone.
Sheela Sathyanarayana: There were very few smokers in our cohort, and these tended to be older women. There were too few smokers to be included in statistical analysis.
Joe Braun (Providence, USA): Your gene-environment interaction study indicated that joint exposure to a Table 5 Linear regression analysis slopes of anogenital outcomes in infants in relation to log-total testosterone, -free testosterone, and estradiol concentrations in pregnant women (nZ180).
Male newborns (nZ94)
Female newborns (nZ86) The lack of antiandrogenicity published for MEP and DEP does not make sense with our findings, however, some publications are more in keeping with our results. We shall continue our studies to see if the effect is persistent.
Joe Braun: Have you performed genotyping on the women who have a positive association between MEP and testosterone? There might be a subgroup with the inverse relationship, which could be consistent with your AGD correlations.
Sheela Sathyanarayana: We have not yet performed genotyping, but this is planned for mothers and fathers in future in the GEAR study (genetics and the environment associated with male reproduction), which will be an improvement on the pilot study.
Hagai Levine (Jerusalem, Israel): In your mixtures study, did you see combined interaction with different genes?
Sheela Sathyanarayana: We have not looked at that in the pilot study because the pool is too low. It might be possible in the bigger cohort of 400 men, but for genetic studies, 400 individuals might not be a large enough number for statistical significance.
Ewa Rajpert-De Meyts (Copenhagen, Denmark): Your experimental design was good when you looked at the level of maternal hormones separately for male and female fetuses. Your cross-sectional assessment of mothers exposed to phthalates indicated reduced maternal serum testosterone in association with male fetuses. Is this due to a combination of effects on the mother and fetus, or is it mainly due to reduced testosterone production by the fetus?
Sheela Sathyanarayana: That is difficult to assess because not many studies have been performed on phthalate exposure in adult women. In the bivariate analysis, pregnant mothers with female fetuses had lower testosterone levels. This might be due to reduced maternal production of testosterone, but there might also be a fetal component in the levels.
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